Want to see CCEL full AI Analyst Report?
Cryo-Cell International (CCEL) AI Stock Analysis
Cryo-Cell International
(NYSE MKT:CCEL)
The score is held back primarily by weak financial quality—TTM net losses, flat/slightly declining revenue, and a notably strained balance sheet with negative equity—despite positive cash generation. Technicals provide meaningful support as price is above key moving averages with positive momentum indicators, while valuation remains a headwind due to a negative P/E and no dividend yield. Corporate governance news is mildly supportive but secondary to the financial risks.
Cryo-Cell International (CCEL) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $40.72M
- Dividend Yield
- ―
- Average Volume (3M)
- 24.51K
- Price to Earnings (P/E)
- -22.5
- Beta (1Y)
- 0.23
- Revenue Growth
- -1.96%
- EPS Growth
- -314.41%
- Country
- US
- Employees
- 74
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Cryo-Cell International Business Overview & Revenue Model
Company Description
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical co...
How the Company Makes Money
CCEL primarily generates revenue from fees associated with private (family) cord blood and cord tissue banking services. The company’s revenue model typically includes: (1) upfront service fees charged at or around the time of birth for collection, p...
Cryo-Cell International Financial Statement Overview
Summary
Overall fundamentals are mixed: cash flow is a relative strength with positive TTM operating and free cash flow, but revenue is flat/slightly down and the company is loss-making on a TTM basis. The biggest constraint is the balance sheet, with deeply negative equity despite reduced debt, which limits financial flexibility and increases risk.
Income Statement
38NegativeBalance Sheet
22NegativeCash Flow
62Positive| Breakdown | TTM | Nov 2025 | Feb 2025 | Nov 2023 | Feb 2023 | Nov 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.13M | 31.57M | 31.99M | 31.34M | 30.34M | 28.88M |
| Gross Profit | 24.26M | 24.19M | 24.04M | 22.90M | 21.54M | 19.90M |
| EBITDA | 1.20M | 1.10M | 1.96M | -10.42M | 6.65M | 5.32M |
| Net Income | -2.82M | -2.43M | 402.10K | -9.52M | 2.77M | 2.08M |
Balance Sheet | ||||||
| Total Assets | 62.30M | 61.73M | 64.68M | 61.22M | 64.89M | 60.66M |
| Cash, Cash Equivalents and Short-Term Investments | 4.23M | 3.30M | 3.50M | 980.25K | 1.72M | 8.34M |
| Total Debt | 577.20K | 11.56M | 12.93M | 10.90M | 11.61M | 2.82M |
| Total Liabilities | 78.70M | 80.33M | 77.89M | 72.25M | 66.41M | 56.48M |
| Stockholders Equity | -16.39M | -18.61M | -13.22M | -11.03M | -1.52M | 4.18M |
Cash Flow | ||||||
| Free Cash Flow | 4.65M | 5.25M | 2.41M | 1.28M | -8.60M | 974.92K |
| Operating Cash Flow | 4.92M | 5.48M | 6.01M | 8.92M | 8.57M | 7.93M |
| Investing Cash Flow | -416.26K | -975.33K | -4.88M | -8.14M | -15.28M | -6.95M |
| Financing Cash Flow | -3.34M | -4.75M | -979.12K | -2.07M | 147.86K | -3.07M |
Cryo-Cell International Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCEL, the sentiment is Positive. The current price of 5.05 is above the 20-day moving average (MA) of 4.62, above the 50-day MA of 4.34, and above the 200-day MA of 3.70, indicating a bullish trend. The MACD of 0.28 indicates Negative momentum. The RSI at 58.79 is Neutral, neither overbought nor oversold. The STOCH value of 79.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CCEL.
Cryo-Cell International Risk Analysis
Cryo-Cell International disclosed 40 risk factors in its most recent earnings report. Cryo-Cell International reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
2 New RisksCryo-Cell International Peers Comparison
Overall Rating
SRTA60Neutral- CCEL52Neutral
CCM40Underperform
AIDX37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SRTA | 60Neutral | $378.64M | -15.27 | -8.86% | ― | 22.73% | 3.40% |
| CCEL | 52Neutral | $43.14M | -22.52 | 15.84% | ― | -1.96% | -314.41% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| CCM | 40Underperform | $15.59M | -0.03 | 5.16% | ― | 20.26% | 69.68% |
| AIDX | 37Underperform | $3.14M | -0.31 | -387.27% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CCEL | Cryo-Cell International | 5.05 | 0.67 | 15.24% | |
| CCM | Concord Medical Services | 3.85 | -1.83 | -32.22% | |
| SRTA | Strata Critical Medical, Inc. | 4.44 | -0.18 | -3.90% | |
| NIVF | Newgenivf Group Limited | 0.85 | -9503.15 | -99.99% | |
| BMGL | Basel Medical Group Ltd | 5.21 | -12.05 | -69.81% | |
| AIDX | 20/20 Biolabs, Inc. | 0.23 | -23.62 | -99.02% |
Cryo-Cell International Corporate Events
Cryo-Cell Shareholders Back Board, Auditor and Pay
PositiveOn October 27, 2026, Cryo-Cell International, Inc. held its Annual Meeting of Stockholders, where shareholders voted on board composition, auditor ratification, and executive pay. Stockholders re-elected four directors, strongly supported the appoint...
Cryo-Cell Sets Record Date for 2026 Shareholder Meeting
NeutralCryo-Cell International’s board of directors has scheduled the company’s 2026 Annual Meeting of Stockholders for October 27, 2026, and set September 21, 2026 as the record date to determine shareholders eligible to receive notice and vote...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026